Xenon Pharmaceuticals Inc
NASDAQ:XENE
Earnings Announcements
Xenon Pharmaceuticals Reports Q1 Results
Published: 05/10/2022 20:12 GMT
Xenon Pharmaceuticals Inc (XENE) - Xenon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update.
Xenon Pharmaceuticals Inc - Qtrly Loss per Share $0.35.
Xenon Pharmaceuticals Inc - Cash and Cash Equivalents and Marketable Securities Were $537.9 Million As of March 31, 2022.
Xenon Pharmaceuticals Inc - Qtrly Loss per Share $0.35.
Xenon Pharmaceuticals Inc - Cash and Cash Equivalents and Marketable Securities Were $537.9 Million As of March 31, 2022.
Revenue is expected to be $4.87 Million
Adjusted EPS is expected to be -$0.47
Next Quarter Revenue Guidance is expected to be $4.7 Million
Next Quarter EPS Guidance is expected to be -$0.57
More details on our Analysts Page.
Adjusted EPS is expected to be -$0.47
Next Quarter Revenue Guidance is expected to be $4.7 Million
Next Quarter EPS Guidance is expected to be -$0.57
More details on our Analysts Page.